Free Newsletter
Sun aims to strongarm Taro shareholders
India's Sun Pharmaceuticals just won't take no for an answer. After its merger deal with Israel's Taro Pharmaceuticals fell apart last month, Sun now says it's going to try to force the company's controlling shareholders to sell out. "We will do everything required to preserve our rights," Sun's chairman said in a statement. Both companies are suing over the collapsed deal. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: